Curocell

Curocell EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Curocell (372320.KQ) as of Oct 27, 2026 is -22.13. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -24.99 — a change of -11.44% (higher).

EV/FCF

-22.13

YoY

-11.44%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Curocell is 2025 -22.13 . EV/FCF (Enterprise Value to Free Cash Flow) of Curocell was 2024 -24.99 . It decreases by -11.44% higher compared to the previous year.

The Curocell EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2021
-34.66 KRW
Jan 1, 2022
-17.38 KRW
Jan 1, 2023
-15.26 KRW
Jan 1, 2024
-24.99 KRW
Jan 1, 2025
-22.13 KRW
The Curocell EV/FCF history
YEAREV/FCFYoY
-22.13-11.44%
-24.99+63.79%
-15.26-12.20%
-17.38-49.87%
-34.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

EV/FCF (Enterprise Value to Free Cash Flow) of Curocell is -22.13 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Curocell changed from -24.99 to -22.13, representing a -11.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Curocell since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Curocell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Curocell

All Key Metrics — Curocell